Medium-term results of heart transplantation using donors over 63 years of age

Evgenij V. Potapov, Matthias Loebe, Michael Hübler, Michele Musci, Manfred Hummel, Yu Guo Weng, Roland Hetzer

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background. The continual shortage of hearts for transplantation (HTx) led to the expansion of the donor pool by accepting older donors. We compared the medium-term follow-up of patients after HTx with older hearts (over the age of 63 years) with those of patients after HTx with younger hearts. Patients and Methods. Since April 1994 we have used hearts for HTx from donors older than the age of 63 years. Until November 1998, 309 HTx and 9 re-HTx were performed in 309 adults with a mean age of 50.7±10.9 years (range 17-68 years). There were 252 men and 57 women. The patients were divided into two groups: group I-donor age under 63 years (296 patients, mean age 50.4±11 years; mean donor age 38.1±13 years; mean follow-up 1.7±1.6 years); group II-donor age of more than 63 years (13 patients, mean age 57.4±5.6 years; mean donor age 65.1±2.1; mean follow-up 2.2±1.6 years). There were no differences in the etiology of heart failure, gender, or ischemia time between the groups. The patients in group II were significantly older (P=0.008). Multiple factors were analyzed in the groups, which included changes in the left/right ventricle ejection fraction, early postoperative mortality (up to 30 days), cumulative survival rates and cardiac- dependent morbidity [myocardial infarction, malignant arrhythmias, coronary stenosis (>50% in one of the main coronary arteries) and transplant vasculopathy]. Additionally, freedom from cytomegalovirus infection (rise of titer or seroconversion) and freedom of acute rejection episodes grade ≥2 (International Society of Heart and Lung Transplantation [ISHLT]) were analyzed. Results. After 1 year mean left and right ventricle ejection fraction were good in both groups and did not significantly change for up to 2 years. No Re-HTx was performed in group II. The early postoperative mortality was similar in both groups (P=0.8). Also, the cumulative survival rates were similar in both groups (P=0.87). Long-term cardiac morbidity was lower in group I (P=0.03). The long-term freedom from cytomegalovirus infection in group I was significantly higher when compared with group II (P=0.0002). The long-term freedom from severe rejection episodes was similar in both groups (P=0.3). Conclusion. The study found a significant increase in long-term cardiac morbidity due to more focal coronary stenosis in group II, and freedom from cytomegalovirus infection, but did not find significant differences in the long-term survival between patients who received hearts from donors of up to 63 years of age and from those more than 63 years. The acceptance of donors older than 63 years old for HTx does not worsen the outcome of the recipients. The careful selection of older donors, with close monitoring of the coronary situation after HTx and expanded indications for revascularization of older hearts, could make HTx with older hearts, even in older recipients, a safe option.

Original languageEnglish (US)
Pages (from-to)1834-1838
Number of pages5
JournalTransplantation
Volume68
Issue number12
StatePublished - Dec 27 1999
Externally publishedYes

Fingerprint

Heart Transplantation
Tissue Donors
Heart Ventricles
Cytomegalovirus Infections
Coronary Stenosis
Morbidity
Survival Rate
Heart-Lung Transplantation
Donor Selection
Mortality
Cardiac Arrhythmias
Coronary Vessels
Ischemia
Heart Failure
Myocardial Infarction
Transplants
Survival

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Potapov, E. V., Loebe, M., Hübler, M., Musci, M., Hummel, M., Weng, Y. G., & Hetzer, R. (1999). Medium-term results of heart transplantation using donors over 63 years of age. Transplantation, 68(12), 1834-1838.

Medium-term results of heart transplantation using donors over 63 years of age. / Potapov, Evgenij V.; Loebe, Matthias; Hübler, Michael; Musci, Michele; Hummel, Manfred; Weng, Yu Guo; Hetzer, Roland.

In: Transplantation, Vol. 68, No. 12, 27.12.1999, p. 1834-1838.

Research output: Contribution to journalArticle

Potapov, EV, Loebe, M, Hübler, M, Musci, M, Hummel, M, Weng, YG & Hetzer, R 1999, 'Medium-term results of heart transplantation using donors over 63 years of age', Transplantation, vol. 68, no. 12, pp. 1834-1838.
Potapov EV, Loebe M, Hübler M, Musci M, Hummel M, Weng YG et al. Medium-term results of heart transplantation using donors over 63 years of age. Transplantation. 1999 Dec 27;68(12):1834-1838.
Potapov, Evgenij V. ; Loebe, Matthias ; Hübler, Michael ; Musci, Michele ; Hummel, Manfred ; Weng, Yu Guo ; Hetzer, Roland. / Medium-term results of heart transplantation using donors over 63 years of age. In: Transplantation. 1999 ; Vol. 68, No. 12. pp. 1834-1838.
@article{ed307a723bdc474b9b9ee17433654767,
title = "Medium-term results of heart transplantation using donors over 63 years of age",
abstract = "Background. The continual shortage of hearts for transplantation (HTx) led to the expansion of the donor pool by accepting older donors. We compared the medium-term follow-up of patients after HTx with older hearts (over the age of 63 years) with those of patients after HTx with younger hearts. Patients and Methods. Since April 1994 we have used hearts for HTx from donors older than the age of 63 years. Until November 1998, 309 HTx and 9 re-HTx were performed in 309 adults with a mean age of 50.7±10.9 years (range 17-68 years). There were 252 men and 57 women. The patients were divided into two groups: group I-donor age under 63 years (296 patients, mean age 50.4±11 years; mean donor age 38.1±13 years; mean follow-up 1.7±1.6 years); group II-donor age of more than 63 years (13 patients, mean age 57.4±5.6 years; mean donor age 65.1±2.1; mean follow-up 2.2±1.6 years). There were no differences in the etiology of heart failure, gender, or ischemia time between the groups. The patients in group II were significantly older (P=0.008). Multiple factors were analyzed in the groups, which included changes in the left/right ventricle ejection fraction, early postoperative mortality (up to 30 days), cumulative survival rates and cardiac- dependent morbidity [myocardial infarction, malignant arrhythmias, coronary stenosis (>50{\%} in one of the main coronary arteries) and transplant vasculopathy]. Additionally, freedom from cytomegalovirus infection (rise of titer or seroconversion) and freedom of acute rejection episodes grade ≥2 (International Society of Heart and Lung Transplantation [ISHLT]) were analyzed. Results. After 1 year mean left and right ventricle ejection fraction were good in both groups and did not significantly change for up to 2 years. No Re-HTx was performed in group II. The early postoperative mortality was similar in both groups (P=0.8). Also, the cumulative survival rates were similar in both groups (P=0.87). Long-term cardiac morbidity was lower in group I (P=0.03). The long-term freedom from cytomegalovirus infection in group I was significantly higher when compared with group II (P=0.0002). The long-term freedom from severe rejection episodes was similar in both groups (P=0.3). Conclusion. The study found a significant increase in long-term cardiac morbidity due to more focal coronary stenosis in group II, and freedom from cytomegalovirus infection, but did not find significant differences in the long-term survival between patients who received hearts from donors of up to 63 years of age and from those more than 63 years. The acceptance of donors older than 63 years old for HTx does not worsen the outcome of the recipients. The careful selection of older donors, with close monitoring of the coronary situation after HTx and expanded indications for revascularization of older hearts, could make HTx with older hearts, even in older recipients, a safe option.",
author = "Potapov, {Evgenij V.} and Matthias Loebe and Michael H{\"u}bler and Michele Musci and Manfred Hummel and Weng, {Yu Guo} and Roland Hetzer",
year = "1999",
month = "12",
day = "27",
language = "English (US)",
volume = "68",
pages = "1834--1838",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Medium-term results of heart transplantation using donors over 63 years of age

AU - Potapov, Evgenij V.

AU - Loebe, Matthias

AU - Hübler, Michael

AU - Musci, Michele

AU - Hummel, Manfred

AU - Weng, Yu Guo

AU - Hetzer, Roland

PY - 1999/12/27

Y1 - 1999/12/27

N2 - Background. The continual shortage of hearts for transplantation (HTx) led to the expansion of the donor pool by accepting older donors. We compared the medium-term follow-up of patients after HTx with older hearts (over the age of 63 years) with those of patients after HTx with younger hearts. Patients and Methods. Since April 1994 we have used hearts for HTx from donors older than the age of 63 years. Until November 1998, 309 HTx and 9 re-HTx were performed in 309 adults with a mean age of 50.7±10.9 years (range 17-68 years). There were 252 men and 57 women. The patients were divided into two groups: group I-donor age under 63 years (296 patients, mean age 50.4±11 years; mean donor age 38.1±13 years; mean follow-up 1.7±1.6 years); group II-donor age of more than 63 years (13 patients, mean age 57.4±5.6 years; mean donor age 65.1±2.1; mean follow-up 2.2±1.6 years). There were no differences in the etiology of heart failure, gender, or ischemia time between the groups. The patients in group II were significantly older (P=0.008). Multiple factors were analyzed in the groups, which included changes in the left/right ventricle ejection fraction, early postoperative mortality (up to 30 days), cumulative survival rates and cardiac- dependent morbidity [myocardial infarction, malignant arrhythmias, coronary stenosis (>50% in one of the main coronary arteries) and transplant vasculopathy]. Additionally, freedom from cytomegalovirus infection (rise of titer or seroconversion) and freedom of acute rejection episodes grade ≥2 (International Society of Heart and Lung Transplantation [ISHLT]) were analyzed. Results. After 1 year mean left and right ventricle ejection fraction were good in both groups and did not significantly change for up to 2 years. No Re-HTx was performed in group II. The early postoperative mortality was similar in both groups (P=0.8). Also, the cumulative survival rates were similar in both groups (P=0.87). Long-term cardiac morbidity was lower in group I (P=0.03). The long-term freedom from cytomegalovirus infection in group I was significantly higher when compared with group II (P=0.0002). The long-term freedom from severe rejection episodes was similar in both groups (P=0.3). Conclusion. The study found a significant increase in long-term cardiac morbidity due to more focal coronary stenosis in group II, and freedom from cytomegalovirus infection, but did not find significant differences in the long-term survival between patients who received hearts from donors of up to 63 years of age and from those more than 63 years. The acceptance of donors older than 63 years old for HTx does not worsen the outcome of the recipients. The careful selection of older donors, with close monitoring of the coronary situation after HTx and expanded indications for revascularization of older hearts, could make HTx with older hearts, even in older recipients, a safe option.

AB - Background. The continual shortage of hearts for transplantation (HTx) led to the expansion of the donor pool by accepting older donors. We compared the medium-term follow-up of patients after HTx with older hearts (over the age of 63 years) with those of patients after HTx with younger hearts. Patients and Methods. Since April 1994 we have used hearts for HTx from donors older than the age of 63 years. Until November 1998, 309 HTx and 9 re-HTx were performed in 309 adults with a mean age of 50.7±10.9 years (range 17-68 years). There were 252 men and 57 women. The patients were divided into two groups: group I-donor age under 63 years (296 patients, mean age 50.4±11 years; mean donor age 38.1±13 years; mean follow-up 1.7±1.6 years); group II-donor age of more than 63 years (13 patients, mean age 57.4±5.6 years; mean donor age 65.1±2.1; mean follow-up 2.2±1.6 years). There were no differences in the etiology of heart failure, gender, or ischemia time between the groups. The patients in group II were significantly older (P=0.008). Multiple factors were analyzed in the groups, which included changes in the left/right ventricle ejection fraction, early postoperative mortality (up to 30 days), cumulative survival rates and cardiac- dependent morbidity [myocardial infarction, malignant arrhythmias, coronary stenosis (>50% in one of the main coronary arteries) and transplant vasculopathy]. Additionally, freedom from cytomegalovirus infection (rise of titer or seroconversion) and freedom of acute rejection episodes grade ≥2 (International Society of Heart and Lung Transplantation [ISHLT]) were analyzed. Results. After 1 year mean left and right ventricle ejection fraction were good in both groups and did not significantly change for up to 2 years. No Re-HTx was performed in group II. The early postoperative mortality was similar in both groups (P=0.8). Also, the cumulative survival rates were similar in both groups (P=0.87). Long-term cardiac morbidity was lower in group I (P=0.03). The long-term freedom from cytomegalovirus infection in group I was significantly higher when compared with group II (P=0.0002). The long-term freedom from severe rejection episodes was similar in both groups (P=0.3). Conclusion. The study found a significant increase in long-term cardiac morbidity due to more focal coronary stenosis in group II, and freedom from cytomegalovirus infection, but did not find significant differences in the long-term survival between patients who received hearts from donors of up to 63 years of age and from those more than 63 years. The acceptance of donors older than 63 years old for HTx does not worsen the outcome of the recipients. The careful selection of older donors, with close monitoring of the coronary situation after HTx and expanded indications for revascularization of older hearts, could make HTx with older hearts, even in older recipients, a safe option.

UR - http://www.scopus.com/inward/record.url?scp=0033611105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033611105&partnerID=8YFLogxK

M3 - Article

C2 - 10628759

AN - SCOPUS:0033611105

VL - 68

SP - 1834

EP - 1838

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -